The involvement of platelet-activating factor in thrombocytopenia and follicular rupture during gonadotropin-induced superovulation in immature rats.
To investigate whether the platelets in the ovaries are activated by the action of platelet-activating factor (PAF) during gonadotropin-induced ovulation, we examined the changes in the platelet count in immature rats after administration of PMSG followed 48 h later by human CG (hCG). The platelet count in the inferior vena cava was significantly decreased 48 h after PMSG administration and was further decreased after hCG administration. When both ovaries of rats were extirpated, the administration of PMSG and hCG did not decrease the platelet count. Subcutaneous administration of a PAF antagonist, Y24180 (0.5-5 mg/kg.6 h), after PMSG injection decreased the number of ova shed in a dose-dependent manner. The decrease in the platelet count induced by the administration of PMSG and hCG was reversed to the level of the untreated control group by Y24180 (2.5 mg/kg.6 h). This inhibitory activity of Y24180 on ovulation and thrombocytopenia was completely reversed by the ip injection of synthetic PAF. Subcutaneous administration of indomethacin (IDM) also reduced the number of ova shed in a dose-dependent manner. However, thrombocytopenia was not reversed by IDM. Moreover, the inhibition of ovulation by IDM was not reversed by synthetic PAF. The present study suggests that: 1) platelets are activated by PAF during gonadotropin-induced ovulation in immature rats; 2) PAF is also involved in the rupture of follicles; 3) the presence of the ovary is indispensable for the generation of PAF in gonadotropin-stimulated immature rats; and 4) the mechanism of PAF action on ovulation may be different from that of prostaglandins.
Li
X M
XM
Department of Gynecology and Obstetrics, Kyoto University Faculty of Medicine, Japan.
Sagawa
N
N
Ihara
Y
Y
Okagaki
A
A
Hasegawa
M
M
Inamori
K
K
Itoh
H
H
Mori
T
T
Ban
C
C
D000818:Animals; D001381:Azepines / Q000494:pharmacology; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology*; D007213:Indomethacin / Q000494:pharmacology; D010060:Ovulation / Q000187:drug effects / Q000502:physiology; D010062:Ovulation Induction; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology*; D015539:Platelet Activation / Q000502:physiology; D010976:Platelet Count; D051381:Rats; D011919:Rats, Inbred Strains; D013480:Superovulation / Q000187:drug effects / Q000502:physiology*; D013921:Thrombocytopenia / Q000209:etiology*; D014230:Triazoles / Q000494:pharmacology; D014682:Vena Cava, Inferior / Q000166:cytology
D001381:Azepines; D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D010972:Platelet Activating Factor; D014230:Triazoles; C068035:4-(2-chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; D007213:Indomethacin